Early administration of the GIP receptor antagonist (Pro3)GIP counters development of hyperglycaemia, glucose intolerance and insulin resistance in genetic obesity.

P.R. Flatt, N. Irwin, P.L. McClean, Brian Green, V.A. Gault, C.J. Bailey, F.P.M. O'Harte

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)108
JournalDiabetologia
Volume49
Issue numberS1
Publication statusPublished - 2006

Cite this